We're all Joining Jacks fight against Duchenne Musculare Dystrophy, are you?

Our Funds 2012-2018

Where our funds go?

Basic Research = Yellow
Preclinical Research = Green
Clinical Trial Support = Blue
Clinical Trials = Orange

 

Project NameResearch/Institution or CompanyProject StatusTotal Grant Award
Preclinical study of the combination of tamoxifen, L-citrulline and metformin Dr Olivier Dorchies

University of Geneva
Ongoing

2018-2020
£20,000
Use of Elastase Inhibitors to Treat DMD Dr Addolorata Pisconti

University of Liverpool
Ongoing

2017-2018
£36,365.00
Duchenne Clinical Research Nurse Alder Hey Children’s Hospital, Liverpool Ongoing

2018-2020
£32,106.50
F2 Neuromuscular Clinical Research Doctor Alder Hey Children’s Hospital, Liverpool Ongoing

2017-2018
£30,513
ST4 Neuromuscular Clinical Research Doctor Alder Hey Children’s Hospital, Liverpool Ongoing

2017-2019
£127,121.00
Tamoxifen Clinical Trial Dr Dirk Fischer

University Children’s Hospital Basel
Ongoing £194,996.99
Tamoxifen Project Manager Dr Dirk Fischer

University Children’s Hospital Basel
Ongoing £97,000
TREAT-NMD DMD Co-Ordinator Role University of Newcastle Ongoing

2015-2020
£78,832.66
Physiotherapist Alder Hey Children’s Hospital, Liverpool Ongoing

2016-2018
£45,960.00
Duchenne Clinical Trial Nurse Royal Victoria Infirmary, Newcastle Ongoing

2017-2018
£22,500
Co-Funded Lectureship for a Clinical Research Lectureship/ Senior Lectureship in Duchenne Muscular Dystrophy Royal Victoria Infirmary, Newcastle Ongoing

2017-2018
£22,500
Assessing the preclinical therapeutic impact of cannabidiol for DMD Dr Keith Foster

The University of Reading
COMPLETE

2014-2016
£6213.09
The Duchenne Forum

Supporting 8 basic research projects
Muscular Dystrophy Campaign COMPLETE

2014-2017
£55,346.00
Gene therapy Solid GT

Boston, USA
COMPLETE

2014-2016
$1,666,666.66
VBP-15

Phase 1 Clinical Trial
Reveragen BioPharma Inc, USA COMPLETE

2014-2015
$400,000.00
DMD Heart Protection Study Dr Spinty

Alder Hey
COMPLETE

2014-2017
£14,000
Phase1/2

Clinical trial of HT-100
Akashi Therapeutics

USA
COMPLETE

2013-2015
$100,000
Developing biomarkers for Utrophin Modulators Summit Corporation

Oxford, UK
COMPLETE

2013-2015
£100,000